Paratek Pharmaceuticals - Stock Price History | PRTK

Historical daily share price chart and data for Paratek Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Paratek Pharmaceuticals as of September 24, 2021 is 5.29.
  • The all-time high Paratek Pharmaceuticals stock closing price was 252.10 on February 03, 2009.
  • The Paratek Pharmaceuticals 52-week high stock price is 11.23, which is 112.3% above the current share price.
  • The Paratek Pharmaceuticals 52-week low stock price is 4.51, which is 14.7% below the current share price.
  • The average Paratek Pharmaceuticals stock price for the last 52 weeks is 6.67.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Paratek Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 4.7512 3.9900 7.1400 2.6700 6.2600 55.33%
2019 4.6483 5.5700 7.2400 2.9300 4.0300 -21.44%
2018 10.9410 18.7500 18.8500 4.8000 5.1300 -71.34%
2017 20.5195 15.6000 28.2000 14.2500 17.9000 16.23%
2016 14.0537 18.2300 18.2300 10.4000 15.4000 -18.82%
2015 25.2218 34.5400 34.5400 15.2500 18.9700 -50.79%
2014 30.4181 40.3361 41.5366 16.0000 38.5500 -4.43%
2013 46.9581 56.9028 79.7119 30.4922 40.3361 -24.49%
2012 83.6523 95.5582 141.0564 51.1405 53.4214 -43.17%
2011 91.5616 89.6759 140.8163 31.5726 93.9976 5.81%
2010 93.5602 80.3121 130.1333 71.5486 88.8355 8.82%
2009 81.6448 252.1008 252.1008 33.6134 81.6327 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.239B $0.047B
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71